Effectiveness of cognitive-behavioral treatment for panic disorder versus treatment as usual in a managed care setting: 2-year follow-up.
Effectiveness of cognitive-behavioral treatment for panic disorder versus treatment as usual in a managed care setting: 2-year follow-up.
复制标题
恐慌症认知行为治疗与管理护理环境中常规治疗的有效性：2 年随访。
DOI：
10.1037/0022-006x.74.2.377
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Mansfield,Abigail
中科院分区：
文献类型：
--
作者：
Addis,MichaelE;Hatgis,Christina;Cardemil,Esteban;Jacob,Karen;Krasnow,AaronD;Mansfield,Abigail
80名符合惊恐障碍标准并接受惊恐控制治疗（PCT; MG Craske， E. Meadows, & DH Barlow, 1994）或在管理护理环境中接受常规治疗（TAU）的患者在急性治疗后1年和2年进行评估。提供PCT的治疗师以前很少或没有接触过认知行为疗法。对全部意向治疗样本的分析显示，在整个随访期间，两种治疗之间没有显著差异。然而，当治疗完成者状态作为调节因素加入时，接受PCT的患者表现出较低的恐慌严重程度和恐惧回避水平，更有可能实现和维持临床显著的改变。随访期间苯二氮卓类药物的使用与接受PCT的患者的恐慌严重程度有关，但在TAU患者中没有发现这种关系。结果讨论了PCT的传播和有效性以及更普遍的循证心理治疗。（PsycInfo数据库记录(c) 2024 APA，版权所有）
Eighty clients meeting criteria for panic disorder and receiving either panic control therapy (PCT; MG Craske, E. Meadows, & DH Barlow, 1994) or treatment as usual (TAU) in a managed care setting were assessed 1 and 2 years following acute treatment. PCT was provided by therapists with little or no previous exposure to cognitive-behavioral therapies. Analyses of the full intent-to-treat sample revealed no significant differences between the treatments across the follow-up period. However, when treatment completer status was added as a moderator, those receiving PCT showed lower levels of panic severity and phobic avoidance and a greater likelihood of achieving and maintaining clinically significant change. Benzodiazepine use during follow-up was associated with greater panic severity for those clients who received PCT, but no such relationship was found for TAU clients. Results are discussed in relation to the dissemination and effectiveness of PCT as well as evidence-based psychotherapies more generally.(PsycInfo Database Record (c) 2024 APA, all rights reserved)
登录
查看更多内容
CA 125 用于在初级治疗期间监测卵巢癌
影响因子：
3.8
作者：
Philip T. Lawn;G. Malkasian;C. Whitney;Jonathan C. Berek;R. Bast
通讯作者：
R. Bast
CA 125 血清水平与卵巢癌患者的二次手术相关。
影响因子：
7.2
作者：
J. Berek;R. Knapp;G. Malkasian;P. Lavin;C. Whitney;J. Niloff;R. Bast
通讯作者：
R. Bast
影响因子：
4.7
作者：
VANDERBURG, MEL;LAMMES, FB;STOTER, G
通讯作者：
STOTER, G
使用 CA-125 预测卵巢癌患者的生存率。
影响因子：
45.3
作者：
G. Rustin;J. Gennings;A. Nelstrop;H. Covarrubias;H. Lambert;K. Bagshawe
通讯作者：
K. Bagshawe